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A Meta-Analysis of Survival Rates of Untreated
Patients in Randomized Clinical Trials of
Hepatocellular Carcinoma
Giuseppe Cabibbo,1,4 Marco Enea,2 Massimo Attanasio,2 Jordi Bruix,3 Antonio Craxı`,1 and Calogero Camma`1,5
Knowing the spontaneous outcome of hepatocellular carcinoma (HCC) is important for
designing randomized controlled trials (RCTs) of new therapeutic approaches; however,
survival of patients in the absence of treatment is highly variable, and prognostic factors
inﬂuencing outcomes are incompletely deﬁned. The aims of this meta-analysis were to
estimate the 1-year and 2-year survival rates of untreated HCC patients enrolled in RCTs of
palliative treatments, and to identify prognostic factors. RCTs evaluating therapies for HCC
with placebo or no-treatment arms were identiﬁed on MEDLINE through April 2009. Data
were combined in a random effect model. Primary outcomes were 1-year and 2-year survival.
Thirty studies met the inclusion criteria. The pooled estimates of the survival rates were
17.5% at 1 year (95% conﬁdence interval [95%CI], 11%-27%; range, 0%-75%) and 7.3% at
2 years (95%CI, 3.9%-13%; range, 0%-50%). Heterogeneity among studies was highly
signiﬁcant (P< 0.0001) both for 1-year and 2-year survival, and persisted when RCTs were
stratiﬁed according to all patient and study features. Through meta-regression, impaired
performance status, Child-Pugh B-C class, and presence of portal vein thrombosis were all
independently associated with shorter survival. Ascites was strongly linked to a worse out-
come in intermediate/advanced Barcelona Clinic Liver Cancer stages. Conclusion: This
meta-analysis conﬁrms the heterogeneity of behavior of untreated HCC and provides a
sound basis for stratifying patients with HCC according to expected survival in future trials
of new anti-cancer agents. (HEPATOLOGY 2010;51:000-000.)
The extensive application of surveillance programsfor early detection of small (5 cm) hepatocellu-lar carcinoma (HCC) has increased the number
of tumors detected within theMilan criteria1 at Barcelona
Clinic Liver Cancer (BCLC) stages 0 or A (very early or
early),2 and potentially responsive to curative treatments,
such as liver transplantation and percutaneous or surgical
ablation.3,4 Nonetheless, most patients with HCC (ap-
proximately 70%) are diagnosed at BCLC B (intermedi-
ate) and C (advanced) stages (approximately 50%) or
BCLC D (end stage, approximately 20%).4
A previous systematic review5 showed that the survival
rates of untreated patients or of those who received pla-
cebo in randomized controlled trials (RCTs) of unresect-
able HCC vary among the studies, ranging from 10% to
72% at 1 year and from 8% to 50% at 2 years.
In the setting of unresectable HCC, an accurate estimate
of survival among untreated patients is essential for (1) eval-
uating the natural history and assessing the validity of bio-
logical or radiological surrogate markers, (2) controlling for
confounding factors in observational studies, (3) calculating
the sample size and stratifying subjects in RCTs, and (4)
assessing treatment effect size to formulate therapeutic strat-
egies. Knowledge of the factors inﬂuencing the outcome of
untreated patients alsomay be important for interpreting the
results of RCTs of different treatments.
Abbreviations: BCLC, Barcelona Clinic Liver Cancer; CI, conﬁdence interval;
ECOG PS, Eastern Cooperative Oncology Group performance status; HBV, hepa-
titis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; RCT, ran-
domized controlled trial.
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Current guidelines for the management of HCC rec-
ommend mortality risk estimates as a decision-making
support.3 Although different palliative treatments (che-
moembolization and recently, sorafenib) have been pro-
posed for patients with HCC, prognosis remains poor. In
BCLC B or C, the survival of treated patients is assumed
to be 10% to 40% at 3 years.6 In end-stage HCC (BCLC
D), the prognosis is very poor, with a median survival of
only 3 months.4 Interpretation of the results of the RCTs
of palliative treatments is problematic, with conﬂicting
data, and there is no consensus for all HCC stages on the
best algorithm of treatment, although chemoemboliza-
tion and sorafenib are currently considered the standard
of care for BCLC B and BCLC C stages, respectively.6
To resolve uncertainty by increasing the statistical
power, we chose to do a meta-analysis of the placebo or
inactive treatment arms of RCTs of palliative treatments
for HCC, with the aims of (1) estimating the 1-year and
2-year rates of survival among patients receiving no treat-
ment, or placebo; (2) analyzing the variability in survival
rates by looking at the heterogeneity among the RCTs as
a means of interpreting this variability; and ﬁnally, (3)
identifying factors associated with a longer survival.
Patients and Methods
Selection of Trials. This analysis was performed in
accordance with the PRISMA (Preferred Reporting Items
for Systematic Reviews and Meta-Analyses) statement.7
The primary sources of the reviewed studies, exclusively
in English, were MEDLINE, CANCERLIT, the Co-
chrane Controlled Trials Register, and the Cochrane Li-
brary, with the following medical subject headings
(MeSH): hepatocellular carcinoma; liver cancer, primary
liver carcinoma; placebo, double-blind; therapy; treatment;
chemoembolization; systemic therapy; randomized or ran-
domised trial, and clinical trial. The search included liter-
ature published through April 2009 with no lower date
limit on the search results. The computer search was sup-
plemented with manual searches for reference lists of all
retrieved review articles, primary studies, and abstracts
from meetings to identify other studies not found in the
computer search. When the results of a single study were
reported in more than one publication, only the most
recent and complete data were included in the meta-anal-
ysis.
Studies were included in the analysis if (1) they were
RCTs comparing any therapy with placebo, no treat-
ment, or supportive care; (2) they includedHCC patients
with or without metastatic disease; (3) 1-year or 2-year
survival was assessed as an outcome measure of the effect
of the treatment; and (4) they had been published or
accepted for publication as full-length articles.
Among the 485 studies reviewed (Fig. 1), 30 RCTs8-37
met the inclusion criteria. Studies were excluded if they
did not have an adequate control arm; if they were non-
randomized or if they enrolled randomized and nonran-
domized patients; and if they were published only in
abstract form. The rationale for excluding studies pub-
lished as abstracts only was that the methodological qual-
ity could not be assessed.
Review of the Trials. The RCTs were reviewed using
a list of predeﬁned, pertinent questions that concerned
the characteristics of patients, treatments, outcomes, and
study validity. Each trial was evaluated and classiﬁed by
three independent investigators (C.C., A.C., and G.C.).
Discrepancies among reviewers were infrequent (overall
interobserver variation of 10%) and were resolved by
discussion.
The methodological quality of the studies was assessed
by ﬁve principal criteria (Supporting Table 1), using those
established by Jadad et al.38 and Ban˜ares et al.,39 as sug-
gested by the Panel of Experts in HCC-Design Clinical
Trials.4 The quality of trials was evaluated according to
each separate component. The maximum possible score
was 10 points.
Statistical Analyses. Pooled estimates of 1-year and
2-year survival rates were calculated using random-effects
logistic regression analysis after applying sample weights
according to the sample size. Heterogeneity among stud-
ies was assessed with the Pearson chi-squared test. Three
different methods were used to explore and explain the
diversity among studies: (1) stratum analysis of variables
suspected of having caused inconsistency, (2) meta-re-
gression, and (3) subgroup analysis. Therefore, stratum-
speciﬁc rates of the 1-year and 2-year survival rates for
different patient-level and study-level covariates were cal-
Fig. 1. Study ﬂowchart.
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culated. We used 16 stratifying variables: publication
year, study validity, study location, mean age, percentage
of males, percentage of alcohol-related liver disease, per-
centage of hepatitis B virus (HBV)–related liver disease,
percentage of hepatitis C virus (HCV)–related liver dis-
ease, percentage of performance status 0 subjects, mean
serum albumin, mean total bilirubin, prothrombin activ-
ity, percentage of solitary tumors, percentage of portal
thrombosis, percentage of Child-Pugh A patients, and
percentage of Okuda stage I patients.
Only univariate logistic regression analyses were used
to examine the association between features of the study
and the 1-year survival rates. We did not consider multi-
variate analysis because of the wide heterogeneity and lack
of complete data for identiﬁcation of possible variables
that could explain heterogeneity. A chi-squared for inter-
action was used to examine whether the 1-year survival
varied signiﬁcantly between subgroups.
Begg’s funnel plots were generated, and Egger’s regres-
sion asymmetry test was used to examine potential publi-
cation bias related to the 1-year survival rates. For all
analyses, P 0.05 was considered statistically signiﬁcant.
All analyses were completed with SAS version 8.1 (SAS
Institute, Cary, NC) software.
Funding/Support. This study was not supported by
any pharmaceutical company or grants; the cost was
borne by the authors’ institutions.
Results
Description of the Studies. After review of the
titles and abstracts, 30 RCTs8-37 fulﬁlled the inclusion
criteria and were selected for review. Twenty stud-
ies9,12-21,23,25,26,28,31,33-35,37 were North American and
European, and 108,10,11,22,24,27,29,30,32,36 were Asian-
Paciﬁc. Of the 30 RCTs, 148-21 were published before
2000, and the other 1622-37 since 2000. The distribu-
tion of the main characteristics of patients in the con-
trol arm of the 30 RCTs8-37 considered in the current
analysis is reported in Table 1. Characteristics of arms (treat-
ment and control) ofRCTs included in themeta-analysis are
detailed in Supporting Table 2. In 15 RCTs, there was an
inactive placebo arm,12,15-17,19,24,25,29,30,32-37 whereas in
the others, untreated patients received no treatment or sup-
portive care only.8-11,13,14,18,20-23,26-28,31
A total of 4335 patients were included in these 30
studies, 1927 of whomwere in the control group. The size
of the control groups in each study ranged from 1112 to
30335 patients. The percentage of men ranged from 6526
to 100.11 Mean patient age was 62.3, ranging from 4911 to
69.34,37 The proportion of patients with cirrhosis ranged
from 6334 to 100%.12,19,20,23
Dataon thecauseof liverdiseaseweremissing inmany trials.
HCV status was not reported in 11 trials,8-12,17,22,24,27,30,37 and
anti-HCV, when reported, was positive in 436 to 94%13 of the
patients. HBV status was not reported in six trials,9,11,12,22,30,37
and hepatitis B surface antigen, when reported, was posi-
tive in 013,23 to 94.4%.10 The proportion of patients with
alcohol-related liver disease was not reported in 13
RCTs,8,10-12,18,22,24,26,27,30,32,34,36 and ranged from 2.525
to 78%31 in studies reporting alcohol consumption.
Among the studies providing data on the distri-
bution of the ECOG Performance Status (ECOG
PS),13,16,17,20,27,28,30,31,32,35-37 the frequency of an
ECOG PS  0 went from 032 to 77%.28 Information
on the presence of ascites was missing from most tri-
als8,11,12,14,15,17-19,21,22,24,25,27,29,30,33-37 and ranged from
8%26 to 63%16 in the studies reporting it. Mean albu-
min levels were comparable in the RCTs, ranging from
3 g/dL26 to 4 g/dL.35 Mean bilirubin levels differed
greatly among RCTs, ranging from 0.7 mg/dL35 to 6.6
mg/dL.18
Only 13 RCTs14,16,18-21,23,25,27-29,33,34 provided informa-
tion about the tumor pattern at diagnosis (solitary versus
multinodular/diffuse). Solitary tumor rates varied greatly,
ranging from 034 to 57%.18 The proportion of patients
with portal vein thrombosis was reported in 20 stud-
ies9,13,14,16,19-23,25-29,31,33-37 and differed greatly among the
trials, ranging from 09,20,28,34 to 65%.22
Methodological quality scores ranged from 412,32 to
1033,35,36 on a scale of 2 to 10 (Supporting Table 3). With
regard to the quality of the studies, all trials except one30
reported an adequate efﬁcacy of randomization, and
only ﬁve studies12,13,19,24,32 did not report an adequate
follow-up. Adequate blinding was used in eight
RCTs.15-17,19,30,33,35,36 Twenty-three trials (77%) showed a
high-quality score (6 points).8-11,14-21,23,26-30,33-37
Survival Rates. The pooled estimate of the 1-year
survival rate was 17.5% (95% conﬁdence interval [CI],
11%-27%; range, 0-75%). There was a statistically signif-
icant heterogeneity among studies, P  0.0001 (Fig. 2).
Logistic regression analysis was used to identify poten-
tial sources of heterogeneity among the studies. Using the
univariate logistic regression, of the 16 variables assessed
only nine were associated with an increase in the 1-year
survival rate: North American and European studies (P
0.001), female sex (P  0.043), low percentage of hepa-
titis B surface antigen–positive patients (P 0.001), high
percentage of ECOG PS 0 patients (P 0.001), high
albumin level (P  0.038), high prothrombin activity
(P  0.001), low percentage of portal vein thrombosis
(P  0.001), high percentage of Child-Pugh class A pa-
tients (P 0.042), and high percentage of Okuda stage I
patients (P  0.001) (Table 2).
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To assess any differences causing heterogeneity within
each stratum of relevant study features, we calculated the
pooled estimates of the 1-year survival rate within each
stratum and evaluated heterogeneity among strata. How-
ever, heterogeneity was equally evident in all strata (Sup-
porting Table 4).
The pooled estimate of the 2-year survival rate was
7.3% (95%CI, 3.9%-13%; range, 0-50%). Again, there
was a statistically signiﬁcant heterogeneity among studies
(P  0.0001) (Fig. 3).
Subgroup Analyses. Subgroup analyses were per-
formed to evaluate whether the 1-year survival was differ-
Fig. 2. Forest plot of 1-year survival rates of the placebo or untreated arms of 30 RCTs using random-effects model. Studies are arranged by
publication year.
Table 2. Predictors of 1-Year Survival Among All Studies
Study Characteristics
Outcome (1-Year Survival)
No. of studies No. of patients  SE P
Publication year 30 1927 0.03 0.05 0.487
Study validity 30 1927 0.21 0.17 0.228
Study location* (2 versus 1) 30 1927 2.01 0.52 0.001
Male sex, % 29 1901 0.06 0.03 0.043
Cause of liver disease
Alcohol, % 17 1381 0.01 0.01 0.413
HCV, % 19 1339 0.01 0.01 0.131
HBV, % 24 1577 0.02 0.01 0.001
ECOG PS 0,† % 12 1126 0.03 0.01 0.001
Albumin, g/dL 15 958 2.34 1.13 0.038
Bilirubin, mg/dL 19 1135 0.19 0.31 0.533
Prothrombin activity, % 11 582 0.13 0.03 0.001
Presence of ascites, % 10 487 0.01 0.02 0.569
Tumor stage
Solitary, % 13 705 0.01 0.02 0.699
Multinodular/massive, % 13 705 0.01 0.02 0.699
Portal vein thrombosis, % 20 1484 0.03 0.01 0.001
Child-Pugh class A, % 18 1459 0.02 0.01 0.042
Okuda stage I, % 18 1103 0.06 0.01 0.001
*For study location, 1 corresponds to North American and European studies; 2 to Asia-Paciﬁc studies.
†Eastern Cooperative Oncology Group—performance status.
HCV, hepatitis C virus; HBV, hepatitis B virus; SE, standard error.
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ent according to the various BCLC stages. Because BCLC
classiﬁcation was speciﬁcally reported only by a minority
of studies,23,28,32,34,35,36 we extrapolated from RCTs that
provided information on Child-Pugh class or Okuda
stage 9,12,13,15,18-30 so that patients belonging to Child-
Pugh class C or to Okuda stage III could be considered
BCLC D stage. Thus, according to the BCLC classiﬁca-
tion, we separated RCTs including only intermediate (B)
and advanced (C) BCLC patients (named BC stage
studies) from those that also included patients in the end-
stage D (named D stage studies).
The pooled estimate of BCLC BC stage 1-year sur-
vival rate was 34% (95%CI, 22-48; range, 3%-75%).
There was a statistically signiﬁcant heterogeneity among
studies, P  0.0001 (Fig. 4A).
The pooled estimate of BCLC B stage 1-year survival
rate was 49.6% (95%CI, 32-75; range, 3%-75%). There
was a statistically signiﬁcant heterogeneity among studies,
P  0.0001 (Supporting Fig. 1A).
The pooled estimate of BCLC C stage 1-year survival
rate was 25% (95%CI, 14-40; range, 3%-63%). There
was a statistically signiﬁcant heterogeneity among studies,
P  0.0001 (Supporting Fig. 1B).
The pooled estimate of BCLC D stage 1-year survival
rate was 11% (95%CI, 4.7-22; range, 0-57%), and there
was a statistically signiﬁcant heterogeneity among studies,
P  0.0001 (Fig. 4B).
We in turn excluded each study to ensure that no single
study would be solely responsible for the heterogeneity of
any result (so-called robust analysis). In all the robust
analyses, heterogeneity among studies was signiﬁcant.
Moreover, in all the sensitivity analyses excluding the 2
RCTs with the highest and the lowest survival rates, het-
erogeneity was signiﬁcant.
Regression analysis for the BC stage studies showed
that six variables were associated with an increased 1-year
survival rate: studies published before 2000 (P 0.001),
low prevalence of alcohol-related disease (P  0.016),
high prevalence ofHCV-related disease (P 0.021), high
percentage of ECOG PS  0 patients (P  0.001), low
percentage of patients with ascites (P  0.001), and
high percentage of Okuda stage I patients (P  0.001)
(Table 3).
Regression analysis for the D stage studies showed that
three variables were associated with an increased 1-year
survival rate: North American and European studies (P
0.006), low percentage of HBV-related disease (P 
0.004), and low percentage of portal vein thrombosis
(P  0.01)
To examine any potential differences in study features,
we next calculated pooled estimates of the 1-year survival
rate within each stratum and evaluated heterogeneity
among strata. However, heterogeneity was equally evi-
dent in all strata (Supporting Table 5).
Fig. 3. Forest plot of 2-year survival rates, using random-effects model, in the placebo or untreated arms of 23 RCTs. Studies are arranged by
publication year.
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Publication Bias. The funnel and the Egger publica-
tion bias plots for 1-year survival rates are shown in Sup-
porting Fig. 2. The plots and the Egger test for
publication bias showed that the risk of having missed or
overlooked trials was signiﬁcant: the P value was 0.0003
with the Egger test.
The funnel and the Egger publication bias plots for
2-year survival rates are shown in Supporting Fig. 3. The
plots and the Egger test for publication bias showed that
the risk of having missed or overlooked trials was signiﬁ-
cant: the P value was 0.003 with the Egger test.
Discussion
The survival rate in the placebo or untreated arm of
RCTs of HCC patients may be a reliable measure of the
spontaneous course of disease and a basic measure for
both calculating sample size and providing a better prog-
nostic stratiﬁcation in RCTs evaluating new drugs or new
multimodal approaches in the palliative setting. Until re-
cently, new agents for patients with advanced HCC
(BCLC stage C) were usually compared with either pla-
cebo or best supportive care. Recently, sorafenib was
shown to signiﬁcantly improve overall survival in two
double-blind phase 3 RCTs,35,36 although other anti-an-
giogenic agents are currently being compared alone or in
combination. Most investigators and clinicians are now
accepting sorafenib as the standard of care, and an expert
panel has recommended it as a standard of care control
arm for future RCTs of ﬁrst-line systemic agents,4,6 if the
new agents are detected to have a powerful signal in phase
1 or 2 investigations.40 As a result, it will be unfeasible to
design future trials with an untreated control arm. The
1-year overall survival rate of 34% obtained in this meta-
analysis in intermediate/advanced untreated controls can
be considered a useful reference value for determining the
sample size of future studies and for obtaining indirect
Fig. 4. Forest plot of 1-year survival rates, using random-effects model, of BC stage studies (A), and Forest plot of 1-year survival rates, using
random-effects model, of D stage studies (B) in the placebo or untreated arms. Studies are arranged by publication year.
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comparisons among different trials estimating drug efﬁ-
cacy. The 1-year survival observed in the control arm of
the SHARP RCT35 was comparable (35%) to that esti-
mated in this meta-analysis, but much higher than that
observed in the Asian Paciﬁc sorafenib study (17.5%).36
While underlining the external validity of the results of
this meta-analysis, this difference prompts a speciﬁc
warning against generalizing results to all patient settings.
Indirect comparison among trials assessing different drugs
is to be discouraged because the different estimates of
drug efﬁcacy could be entirely related to the different
baseline risks of the populations studied.
This meta-analysis of aggregated data from the placebo
or untreated arms of 30 RCTs of palliative treatment in
HCC clearly demonstrates that the heterogeneity of
1-year and 2-year survival is a common feature of these
studies. There were signiﬁcant differences between the
studies, with observed survival rates ranging from 0%-
75% at 1 year and from 0%-50% at 2 years. In our anal-
ysis, the pooled survival rate estimated by the random
effects model was 17.5% at 1 year and 6.9% at 2 years.
Although the number of included patients in the available
studies was large, suggesting robustness of the estimated
survival rates, the conﬁdence intervals of the estimates at 1
year (95%CI, 11%-27%) and 2 years (95%CI, 3.5%-
13%) remain wide. This inconsistency among RCTs of
palliative treatments for HCC is not surprising if one
considers all potential biases in the selection of patients
with different demographic and clinical characteristics,
different timing of referral and diagnostic criteria, true
differences in case mix, cause, severity of the underlying
cirrhosis, and tumor burden in terms of number and size
of HCC nodules and of presence of macrovascular inva-
sion or extrahepatic spread. An attempt to explain the
wide variability in the natural course of eligible to pallia-
tive treatment of HCC was made by stratifying studies
according to variables that described the patients studied
and the study design features. However, a signiﬁcant het-
erogeneity in survival among RCTs remained even after
stratifying patients and study features, and heterogeneity
in the survival rates persisted even in the stratum of high-
quality studies, implying that this was not explained by
study validity alone. Therefore, the evaluation of the
methodological quality did not seem to inﬂuence the vari-
ability of the assessed outcome, because of the mean high
quality of the studies (75% of these RCTs were high-
quality studies). Heterogeneity of these rates among
RCTsmay reﬂect both inclusion of patients with different
stages of disease and variability in the molecular charac-
teristics and biological behavior of the tumor, which are
not included in any of the currently available staging sys-
tems.
In our analysis, when studies were separated according
to the BCLC stage, the 1-year survival wasmuch higher in
RCTs including only BCLC B or C patients (34%) than
in those also including BCLC D patients (11%). This
provides further evidence that the BCLC staging system
has a good discriminative capacity for prognosticating
Table 3. Predictors of 1-Year Survival Among BC Stage Studies
Study Characteristics
Outcome (1-Year Survival)
No. of studies No. of patients  SE P
Publication year 11 780 0.08 0.02 0.001
Study validity 11 780 0.03 0.83 0.686
Study location* (2 versus 1) 11 780 2.92 0.60 0.124
Male sex, % 11 780 0.01 0.04 0.787
Cause of liver disease
Alcohol, % 6 605 0.01 0.01 0.016
HCV, % 8 593 0.02 0.01 0.021
HBV, % 9 632 0.01 0.01 0.097
ECOG PS 0,† % 8 711 0.03 0.01 0.001
Albumin, g/dL 7 526 1.43 1.45 0.316
Bilirubin, mg/dL 7 526 0.03 0.61 0.960
Prothrombin activity, % 4 165 0.07 0.10 0.473
Presence of ascites, % 5 184 0.03 0.01 0.001
Tumor stage
Solitary, % 6 234 0.06 0.03 0.102
Multinodular/massive, % 6 234 0.06 0.03 0.102
Portal vein thrombosis, % 9 750 0.01 0.01 0.536
Child-Pugh class A, % 7 611 0.01 0.01 0.224
Okuda stage I, % 7 234 0.03 0.01 0.001
*Study location 1 corresponds to North American and European studies; 2 to Asian-Paciﬁc studies.
†Eastern Cooperative Oncology Group—performance status.
HCV, hepatitis C virus; HBV, hepatitis B virus; SE, standard error.
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survival not only in patients with early HCC41 but also in
those with intermediate/advanced HCC. However, data
on direct BCLC stage were lacking in several trials, and
caution must be exercised when interpreting results from
subgroup exploratory analyses. We found by meta-regres-
sion analysis that ECOG performance status and portal
vein thrombosis are robust predictors of death in un-
treated patients as reported by Tandon andGarcia-Tsao42
in a recent systematic review of 72 studies on prognostic
indicators in HCC. These two individual parameters,
both included in the BCLC classiﬁcation, may explain in
large part why this staging system provides accurate infor-
mation on prognosis in the setting of HCC.
A remarkable difference in survival was found between
occidental (North American and European) and oriental
(Asia-Paciﬁc) studies. The high prevalence of HBV-re-
lated liver disease found in Asia-Paciﬁc countries may
account for the different survival observed between orien-
tal and occidental studies in which a high prevalence of
HCV-related liver disease was observed. However, the
potential role of HBV as a prognostic factor disappears
when Asian-Paciﬁc location of the studies and HBV-re-
lated disease were both included in a multivariate model.
The survival differences between occidental and Asian
studies may be explained by differences in the distribution
of other risk and prognostic factors. In fact, the worse
survival observed in the Asia-Paciﬁc study36 could be ex-
plained by the higher prevalence of patients in advanced
stage than in the SHARP study.35
Subgroup analysis of RCTs including only patients in
BCLC intermediate (B) or advanced (C) stages provides
further evidence that clinically detected ascites is strongly
linked to poor survival. The prognostic value of ascites
determines the importance of subclassifying the interme-
diate stage in relation to the therapeutic option. We be-
lieve that the beneﬁts of transarterial chemoembolization
(TACE) may outweigh the risks for BCLC B patients
with Child-Pugh class A or B cirrhosis without ascites,
whereas the risks may outweigh the beneﬁts for BCLC B
patients with Child-Pugh class A or B cirrhosis with as-
cites. Recently, in the subgroup analysis of the SHARP
RCT,43 based on BCLC stages, a trend for overall survival
beneﬁt was found in patients with BCLC B stage disease
treated with sorafenib. However, the small sample size
may have affected the study’s ability to achieve statistical
signiﬁcance. Further large studies of BCLC B intermedi-
ate stage that stratify Child-Pugh class B patients accord-
ing to ascites are needed to avoid overtreatment by TACE
and to conﬁrm the beneﬁt of sorafenib in patients with
BCLC B stage.
We found a signiﬁcant difference in the pooled survival
rates among the strata. In particular, studies published
before 2000 showed a 1-year survival rate higher than
studies published after 2000, perhaps indicating the in-
clusion of a high number of patients in advanced stages in
recent years.
The meta-analysis was performed using summary data,
and more detailed comparisons of survival could be made
with a meta-analysis of individual patient data. However, it
may not always be possible to obtain individual patient data
from all the studies, raising the issue that the studies for
which data are available may represent a biased subset of the
available studies. As with allmeta-analyses, themethodology
of the current study results in a potential limitation of the
generalizability of its results to new populations and settings,
because these were obtained in small RCTs performed in
highly specialized centers. Furthermore, our study is limited
by the patient-level covariates reported in each of the studies,
which are not consistent across trials, representing a further
source of heterogeneity.
Lack of data on other potential confounders, such as
microscopic vascular invasion, histological grading, and
gene proﬁling, also could affect the accuracy of the results.
Finally, we should be especially concerned about pub-
lication bias in settings in which many small studies are
being conducted. The risk of havingmissed or overlooked
trials in the setting of studies assessing mortality in pa-
tients with HCC was substantial. Therefore, it is likely
that small studies with a low rate of mortality or small
drug (or new treatment) effect remain preferentially un-
published. However, the single large placebo-controlled
trial,44 still unpublished as a full paper, reported 1-year
and 2-year survival rates similar to that given in this meta-
analysis.
In untreated HCC patients, the available evidence is
sufﬁcient to conclude that (1) the 1-year and 2-year sur-
vival is extremely variable, and no single patient or study
characteristic can explain this heterogeneity; (2) bad per-
formance status, Child-Pugh B-C classes, and presence of
portal vein thrombosis are associated with a worse prog-
nosis; and (3) the presence of ascites is associated with
poor survival in intermediate/advanced BCLC stages.
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